[{"id":"b0107240-c9ff-4b67-b853-211b0d9cdc8e","acronym":"","url":"https://clinicaltrials.gov/study/NCT07469774","created_at":"2026-03-28T01:44:13.768Z","updated_at":"2026-03-28T01:44:13.768Z","phase":"Phase 1/2","brief_title":"BC3195 in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT07469774","lead_sponsor":"Biocity Biopharmaceutics Co., Ltd.","biomarkers":" EGFR • BRAF • ALK • MET • NTRK","pipe":" | ","alterations":" MET exon 14 mutation","tags":["EGFR • BRAF • ALK • MET • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET exon 14 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 111","initiation":"Initiation: 03/17/2026","start_date":" 03/17/2026","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2026-03-13"},{"id":"18a3da62-b5a9-4d54-8e87-dde3f9c60f1b","acronym":"HARMONI","url":"https://clinicaltrials.gov/study/NCT07211139","created_at":"2025-10-11T01:28:12.030Z","updated_at":"2025-10-11T01:28:12.030Z","phase":"","brief_title":"Head and Neck Advanced Research for Multi-Omics and Optimized Immunotherapy","source_id_and_acronym":"NCT07211139 - HARMONI","lead_sponsor":"Samsung Medical Center","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 07/08/2025","start_date":" 07/08/2025","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-10-07"},{"id":"87abc85a-8507-4bc1-aa8b-b9b9b0d2d2c7","acronym":"HOPE","url":"https://clinicaltrials.gov/study/NCT07190573","created_at":"2025-09-27T08:41:15.516Z","updated_at":"2025-09-27T08:41:15.516Z","phase":"","brief_title":"Head and Neck Cancer Omics/Integrated Precision Medicine (HOPE)","source_id_and_acronym":"NCT07190573 - HOPE","lead_sponsor":"Samsung Medical Center","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"],"overall_status":"Recruiting","enrollment":" Enrollment 350","initiation":"Initiation: 04/25/2025","start_date":" 04/25/2025","primary_txt":" Primary completion: 01/31/2030","primary_completion_date":" 01/31/2030","study_txt":" Completion: 01/31/2030","study_completion_date":" 01/31/2030","last_update_posted":"2025-09-24"},{"id":"883429dd-80b1-4a90-8bbc-e9d0771addf2","acronym":"","url":"https://clinicaltrials.gov/study/NCT07135804","created_at":"2025-08-30T14:01:57.585Z","updated_at":"2025-08-30T14:01:57.585Z","phase":"Phase 2","brief_title":"Iparomlimab and Tuvonralimab Injection for Untreated Locally Advanced Nasopharyngeal Carcinoma","source_id_and_acronym":"NCT07135804","lead_sponsor":"Second Affiliated Hospital of Nanchang University","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 09/01/2025","start_date":" 09/01/2025","primary_txt":" Primary completion: 04/30/2028","primary_completion_date":" 04/30/2028","study_txt":" Completion: 04/30/2031","study_completion_date":" 04/30/2031","last_update_posted":"2025-08-22"},{"id":"c1e23e3e-f08f-4c83-8bab-2ac3f776fe0a","acronym":"","url":"https://clinicaltrials.gov/study/NCT07088861","created_at":"2025-08-02T14:24:41.757Z","updated_at":"2025-08-02T14:24:41.757Z","phase":"","brief_title":"Validation of the 9th AJCC Staging System for NPC in Non-High-Incidence Areas in China","source_id_and_acronym":"NCT07088861","lead_sponsor":"Lirong Wu","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1401","initiation":"Initiation: 01/26/2011","start_date":" 01/26/2011","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-07-28"},{"id":"2006a2aa-ecdd-452a-aec0-f278d895e6f1","acronym":"OTELLO","url":"https://clinicaltrials.gov/study/NCT07064369","created_at":"2025-07-19T14:09:59.980Z","updated_at":"2025-07-19T14:09:59.980Z","phase":"","brief_title":"Observational Study on Thyroid Tumors and EvaLuation of the roLe of New pOntential Predictive/Prognostic Factors","source_id_and_acronym":"NCT07064369 - OTELLO","lead_sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"],"overall_status":"Enrolling by invitation","enrollment":" Enrollment 100","initiation":"Initiation: 02/28/2025","start_date":" 02/28/2025","primary_txt":" Primary completion: 05/01/2029","primary_completion_date":" 05/01/2029","study_txt":" Completion: 09/01/2029","study_completion_date":" 09/01/2029","last_update_posted":"2025-07-14"},{"id":"7f4c6188-6f95-4f28-ad01-406cc4472186","acronym":"","url":"https://clinicaltrials.gov/study/NCT07041788","created_at":"2025-06-28T13:37:36.873Z","updated_at":"2025-06-28T13:37:36.873Z","phase":"Phase 2","brief_title":"Iparomlimab and Tuvonralimab Combined With SFRT and Definitive Chemoradiotherapy in Locoregionally Advanced Bulky HNSCC","source_id_and_acronym":"NCT07041788","lead_sponsor":"Second Affiliated Hospital of Nanchang University","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • docetaxel • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 07/10/2025","start_date":" 07/10/2025","primary_txt":" Primary completion: 07/09/2028","primary_completion_date":" 07/09/2028","study_txt":" Completion: 07/09/2030","study_completion_date":" 07/09/2030","last_update_posted":"2025-06-27"},{"id":"cc4251d0-e106-4faa-b5dd-5c8373253473","acronym":"","url":"https://clinicaltrials.gov/study/NCT06940180","created_at":"2025-06-28T13:40:14.934Z","updated_at":"2025-06-28T13:40:14.934Z","phase":"Phase 2","brief_title":"Toripalimab With Chemotherapy for Sinus Cancer","source_id_and_acronym":"NCT06940180","lead_sponsor":"Glenn J. Hanna","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • docetaxel • Loqtorzi (toripalimab-tpzi)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 06/17/2025","start_date":" 06/17/2025","primary_txt":" Primary completion: 02/01/2028","primary_completion_date":" 02/01/2028","study_txt":" Completion: 02/01/2029","study_completion_date":" 02/01/2029","last_update_posted":"2025-06-26"},{"id":"38ae3e19-8dad-4b01-a570-b25b5bcb525a","acronym":"","url":"https://clinicaltrials.gov/study/NCT06919666","created_at":"2025-06-21T13:16:45.845Z","updated_at":"2025-06-21T13:16:45.845Z","phase":"Phase 1/2","brief_title":"NT219 Combined With Standard of Care Biologic Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma","source_id_and_acronym":"NCT06919666","lead_sponsor":"University of Colorado, Denver","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Erbitux (cetuximab) • NT219"],"overall_status":"Recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 06/01/2025","start_date":" 06/01/2025","primary_txt":" Primary completion: 02/01/2030","primary_completion_date":" 02/01/2030","study_txt":" Completion: 02/01/2031","study_completion_date":" 02/01/2031","last_update_posted":"2025-06-18"},{"id":"41e9d17f-953a-4dba-af2f-1c2f8cab199a","acronym":"","url":"https://clinicaltrials.gov/study/NCT06905561","created_at":"2025-06-07T14:12:34.198Z","updated_at":"2025-06-07T14:12:34.198Z","phase":"","brief_title":"Topical Diclofenac for Prevention of Radiation-induced Dermatitis","source_id_and_acronym":"NCT06905561","lead_sponsor":"The Second Affiliated Hospital of Hainan Medical University","biomarkers":" IL4","pipe":"","alterations":" ","tags":["IL4"],"overall_status":"Recruiting","enrollment":" Enrollment 156","initiation":"Initiation: 02/13/2025","start_date":" 02/13/2025","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-06-06"},{"id":"3633dcfa-95c2-4d04-aaa1-efcdb653ee34","acronym":"","url":"https://clinicaltrials.gov/study/NCT02555176","created_at":"2025-09-06T19:01:30.890Z","updated_at":"2025-09-06T19:01:30.890Z","phase":"","brief_title":"Low-Carbohydrate Normocaloric Diet in Patients With Head and Neck Carcinoma (HNC)","source_id_and_acronym":"NCT02555176","lead_sponsor":"Sidney Kimmel Cancer Center at Thomas Jefferson University","biomarkers":" IGF1","pipe":"","alterations":" ","tags":["IGF1"],"overall_status":"Completed","enrollment":" Enrollment 7","initiation":"Initiation: 12/14/2016","start_date":" 12/14/2016","primary_txt":" Primary completion: 01/01/2017","primary_completion_date":" 01/01/2017","study_txt":" Completion: 10/01/2018","study_completion_date":" 10/01/2018","last_update_posted":"2025-05-20"},{"id":"17d5dfd7-684d-4f90-850e-e14953c32f5a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04091867","created_at":"2021-01-18T20:01:30.016Z","updated_at":"2025-02-25T12:37:25.866Z","phase":"Phase 1","brief_title":"sEphB4-HSA With RT+Chemo or Cetux in Patients With Intermediate to High Risk LAHNSCC","source_id_and_acronym":"NCT04091867","lead_sponsor":"University of Colorado, Denver","biomarkers":" EPHB4","pipe":" | ","alterations":" EGFR expression • CDKN2A negative","tags":["EPHB4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression • CDKN2A negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • cisplatin • carboplatin • sEphB4-HSA"],"overall_status":"Completed","enrollment":" Enrollment 3","initiation":"Initiation: 01/06/2020","start_date":" 01/06/2020","primary_txt":" Primary completion: 05/14/2021","primary_completion_date":" 05/14/2021","study_txt":" Completion: 10/25/2022","study_completion_date":" 10/25/2022","last_update_posted":"2025-02-24"},{"id":"3b32d8a5-c5ea-4195-a505-ea0c6246c9c2","acronym":"","url":"https://clinicaltrials.gov/study/NCT04119024","created_at":"2021-01-18T20:07:53.813Z","updated_at":"2025-02-25T12:27:21.879Z","phase":"Phase 1","brief_title":"Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors","source_id_and_acronym":"NCT04119024","lead_sponsor":"Jonsson Comprehensive Cancer Center","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Imunace (teceleukin) • MB-101 • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 11/27/2019","start_date":" 11/27/2019","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2025-02-24"},{"id":"6c31d924-416a-4fac-90f3-4e9e04970c2d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04708470","created_at":"2021-01-19T20:51:59.772Z","updated_at":"2025-02-25T12:27:53.092Z","phase":"Phase 1/2","brief_title":"A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers","source_id_and_acronym":"NCT04708470","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • CD4","pipe":" | ","alterations":" PD-L1 negative","tags":["PD-L1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jingzhuda (entinostat) • bintrafusp alfa (M7824) • PDS01ADC"],"overall_status":"Recruiting","enrollment":" Enrollment 107","initiation":"Initiation: 10/05/2021","start_date":" 10/05/2021","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-02-24"},{"id":"e6b99f28-6a26-4cf9-aa0c-52200cf1061c","acronym":"ECOG-ACRIN EA3202","url":"https://clinicaltrials.gov/study/NCT05063552","created_at":"2021-10-01T12:54:14.078Z","updated_at":"2025-02-25T12:28:23.682Z","phase":"Phase 2/3","brief_title":"Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers","source_id_and_acronym":"NCT05063552 - ECOG-ACRIN EA3202","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Erbitux (cetuximab) • cisplatin • Tecentriq (atezolizumab) • carboplatin • docetaxel • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn)"],"overall_status":"Recruiting","enrollment":" Enrollment 430","initiation":"Initiation: 03/13/2023","start_date":" 03/13/2023","primary_txt":" Primary completion: 12/15/2027","primary_completion_date":" 12/15/2027","study_txt":" Completion: 12/15/2027","study_completion_date":" 12/15/2027","last_update_posted":"2025-02-24"},{"id":"0b405f7d-3f61-4823-b79f-2d25bdb0eeb2","acronym":"SGNPDL1V-001","url":"https://clinicaltrials.gov/study/NCT05208762","created_at":"2023-05-26T17:05:40.425Z","updated_at":"2025-02-25T13:49:21.100Z","phase":"Phase 1","brief_title":"A Study of SGN-PDL1V in Advanced Solid Tumors","source_id_and_acronym":"NCT05208762 - SGNPDL1V-001","lead_sponsor":"Seagen Inc.","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • PF-08046054"],"overall_status":"Recruiting","enrollment":" Enrollment 315","initiation":"Initiation: 10/25/2022","start_date":" 10/25/2022","primary_txt":" Primary completion: 11/18/2027","primary_completion_date":" 11/18/2027","study_txt":" Completion: 11/17/2028","study_completion_date":" 11/17/2028","last_update_posted":"2025-02-21"},{"id":"dc06b6ac-0a69-4fa1-bf0d-291d63c5c2bc","acronym":"HERTHENA-PanTumor01","url":"https://clinicaltrials.gov/study/NCT06172478","created_at":"2023-12-15T19:20:07.848Z","updated_at":"2025-02-25T13:41:58.738Z","phase":"Phase 2","brief_title":"A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT06172478 - HERTHENA-PanTumor01","lead_sponsor":"Daiichi Sankyo","biomarkers":" ERBB3","pipe":"","alterations":" ","tags":["ERBB3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e patritumab deruxtecan (U3-1402)"],"overall_status":"Recruiting","enrollment":" Enrollment 400","initiation":"Initiation: 02/26/2024","start_date":" 02/26/2024","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 04/30/2026","study_completion_date":" 04/30/2026","last_update_posted":"2025-02-21"},{"id":"ed7a2006-5e7e-462b-a374-549a902e3ba9","acronym":"STX-478-101","url":"https://clinicaltrials.gov/study/NCT05768139","created_at":"2024-01-30T16:19:49.137Z","updated_at":"2025-02-25T13:41:27.084Z","phase":"Phase 1/2","brief_title":"First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors","source_id_and_acronym":"NCT05768139 - STX-478-101","lead_sponsor":"Scorpion Therapeutics, Inc.","biomarkers":" PIK3CA","pipe":" | ","alterations":" PIK3CA mutation","tags":["PIK3CA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Kisqali (ribociclib) • fulvestrant • tersolisib (LY4064809)"],"overall_status":"Recruiting","enrollment":" Enrollment 400","initiation":"Initiation: 04/17/2023","start_date":" 04/17/2023","primary_txt":" Primary completion: 02/28/2027","primary_completion_date":" 02/28/2027","study_txt":" Completion: 02/28/2029","study_completion_date":" 02/28/2029","last_update_posted":"2025-02-21"},{"id":"168840e4-a367-4523-bec5-a87bb18a9b81","acronym":"NT-175-201","url":"https://clinicaltrials.gov/study/NCT05877599","created_at":"2023-05-26T15:07:05.809Z","updated_at":"2025-02-25T13:55:14.477Z","phase":"Phase 1","brief_title":"A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation","source_id_and_acronym":"NCT05877599 - NT-175-201","lead_sponsor":"AstraZeneca","biomarkers":" TP53 • HLA-A","pipe":" | ","alterations":" TP53 mutation • HLA-A*02:01","tags":["TP53 • HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • HLA-A*02:01"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • NT-175"],"overall_status":"Recruiting","enrollment":" Enrollment 162","initiation":"Initiation: 07/12/2023","start_date":" 07/12/2023","primary_txt":" Primary completion: 09/01/2028","primary_completion_date":" 09/01/2028","study_txt":" Completion: 08/01/2039","study_completion_date":" 08/01/2039","last_update_posted":"2025-02-20"},{"id":"34e7c443-a4b5-4fa2-810c-e931f9bf2ab9","acronym":"SGNEGFRd2-001","url":"https://clinicaltrials.gov/study/NCT05983133","created_at":"2023-08-09T14:09:24.911Z","updated_at":"2025-02-25T13:55:26.636Z","phase":"Phase 1","brief_title":"A Study of SGN-EGFRd2 in Advanced Solid Tumors","source_id_and_acronym":"NCT05983133 - SGNEGFRd2-001","lead_sponsor":"Seagen Inc.","biomarkers":" EGFR • ALK • MSI","pipe":" | ","alterations":" EGFR mutation • MSI-H/dMMR • ALK rearrangement","tags":["EGFR • ALK • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • MSI-H/dMMR • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PF-08046052"],"overall_status":"Recruiting","enrollment":" Enrollment 275","initiation":"Initiation: 11/14/2023","start_date":" 11/14/2023","primary_txt":" Primary completion: 07/31/2027","primary_completion_date":" 07/31/2027","study_txt":" Completion: 09/30/2028","study_completion_date":" 09/30/2028","last_update_posted":"2025-02-20"},{"id":"3bf414c0-2141-4ef6-8218-6aca96f23937","acronym":"CHECK'UP","url":"https://clinicaltrials.gov/study/NCT03412058","created_at":"2021-03-04T17:52:48.409Z","updated_at":"2025-02-25T13:52:30.402Z","phase":"","brief_title":"Identifying the Predictive Factors of Response to PD-1 or PD-L1 Antagonists","source_id_and_acronym":"NCT03412058 - CHECK'UP","lead_sponsor":"UNICANCER","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" PD-L1 expression • PD-L1 overexpression • ALK negative","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-L1 overexpression • ALK negative"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 670","initiation":"Initiation: 06/27/2018","start_date":" 06/27/2018","primary_txt":" Primary completion: 01/02/2024","primary_completion_date":" 01/02/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2025-02-20"},{"id":"4405fdfb-3952-4954-a472-701ca7d88a54","acronym":"","url":"https://clinicaltrials.gov/study/NCT05821777","created_at":"2023-04-20T14:03:54.395Z","updated_at":"2025-02-25T13:49:46.186Z","phase":"Phase 1/2","brief_title":"A Study to Evaluate Safety, Tolerability and Preliminary Activity of LB101 in Participants with Advanced Solid Tumors","source_id_and_acronym":"NCT05821777","lead_sponsor":"Centessa Pharmaceuticals (UK) Limited","biomarkers":" PD-L1 • MSI","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e itanistomig (LB101)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 03/28/2023","start_date":" 03/28/2023","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 01/05/2027","study_completion_date":" 01/05/2027","last_update_posted":"2025-02-20"},{"id":"659160cb-410e-4379-bdd3-f303bb40e1fd","acronym":"","url":"https://clinicaltrials.gov/study/NCT05094336","created_at":"2021-10-26T20:53:08.844Z","updated_at":"2025-02-25T13:54:05.475Z","phase":"Phase 1/2","brief_title":"A Study of AMG 193 in Subjects With Advanced MTAP-[] Solid Tumors","source_id_and_acronym":"NCT05094336","lead_sponsor":"Amgen","biomarkers":" CDKN2A • MTAP","pipe":"","alterations":" ","tags":["CDKN2A • MTAP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • AMG 193"],"overall_status":"Recruiting","enrollment":" Enrollment 649","initiation":"Initiation: 02/01/2022","start_date":" 02/01/2022","primary_txt":" Primary completion: 08/02/2026","primary_completion_date":" 08/02/2026","study_txt":" Completion: 06/30/2028","study_completion_date":" 06/30/2028","last_update_posted":"2025-02-20"},{"id":"72d8c724-8d53-4e69-afd5-a79ba1831075","acronym":"REMAIN","url":"https://clinicaltrials.gov/study/NCT06029270","created_at":"2023-09-08T20:10:10.653Z","updated_at":"2025-02-25T13:55:33.082Z","phase":"Phase 2","brief_title":"Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer","source_id_and_acronym":"NCT06029270 - REMAIN","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • LAG3","pipe":"","alterations":" ","tags":["PD-L1 • LAG3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • cisplatin • carboplatin • gemcitabine • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 156","initiation":"Initiation: 07/15/2024","start_date":" 07/15/2024","primary_txt":" Primary completion: 04/30/2029","primary_completion_date":" 04/30/2029","study_txt":" Completion: 04/30/2029","study_completion_date":" 04/30/2029","last_update_posted":"2025-02-20"}]